Study details
Enrolling now
Alpha Radiation Emitters Device for Pancreatic Cancer Treatment
Alpha Tau Medical LTD.
NCT IDNCT06698458ClinicalTrials.gov data as of Apr 2026
Target enrollment
30
Study length
about 1.5 years
Ages
18–120
Locations
13 sites in AZ, CA, FL +3
About this study
This trial is testing a new device, called DaRT, used with chemotherapy to treat pancreatic cancer. The goal is to see if the device is safe when combined with chemotherapy and to assess its effectiveness in treating the cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Primary goalSafety -Serious adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Safety -Serious adverse events
Secondary: Complete or pain response
Body systems
Oncology